The Wnt proteins are a family of secreted signaling molecules essential for embryogenesis, tissue homeostasis, and stem cell fate.^[@ref1]−[@ref3]^ Wnt signaling is regulated by diverse mechanisms, including inhibitory binding proteins (Dickkopf proteins^[@ref4]^) and post-translational modifications (PTMs). Prominent among the PTMs that regulate Wnts is the *O*-palmitoleoylation of a conserved serine residue, which is required for Wnt trafficking, signaling, and interactions with Frizzled receptors.^[@ref5]^ An MBOAT acyltransferase porcupine (PORCN)^[@ref6]^ catalyzes the *O*-palmitoleoylation of Wnts and is a potential therapeutic target for cancers that depend on Wnt signaling for growth.^[@ref7]^ While the role that PORCN plays in Wnt fatty acylation has been understood for more than a decade, a protein involved in deacylating Wnts was only recently identified. This protein, termed NOTUM, had long been recognized to antagonize Wnt pathways based on genetic studies,^[@ref8],[@ref9]^ but it was not until 2015 that two groups independently elucidated the biochemical function of NOTUM as a serine hydrolase that deactivates Wnt proteins by removing the *O*-linked palmitoleate modification.^[@ref10],[@ref11]^ NOTUM expression is itself regulated by Wnt signaling and may serve as a biomarker for Wnt-dependent cancers that are sensitive to PORCN inhibitors.^[@ref12]^ NOTUM may conversely constitute a drug target for degenerative diseases that would benefit from enhanced Wnt signaling, such as osteopenia and osteoporosis.^[@ref13]^

To date, only a handful of NOTUM inhibitors have been described, representing heteroaryl-fused thiophenes.^[@ref14],[@ref15]^ These compounds presumably act as reversible inhibitors, but their selectivity both within and outside of the serine hydrolase family remains unknown. Past efforts by our lab and others have demonstrated that activated carbamates^[@ref16],[@ref17]^ and ureas^[@ref18]^ serve as a versatile source of irreversible inhibitors of serine hydrolases, especially when coupled with activity-based protein profiling (ABPP)^[@ref19],[@ref20]^ to optimize potency and selectivity. In these past studies, however, NOTUM had not been screened by ABPP, presumably because the enzyme is secreted and has a very restricted cell and tissue distribution (<http://biogps.org>). Here, we show that NOTUM can be evaluated by ABPP using the conditioned media (CM) from transfected HEK293T cells (recombinant NOTUM) or SW620 cells (endogenous NOTUM). From a structurally diverse collection of activated carbamates and ureas, we discovered a set of *N*-hydroxyhydantoin (NHH) carbamates that act as potent and selective inhibitors of NOTUM. We show that these compounds are functional at sustaining Wnt signaling in the presence of NOTUM and can be converted into tailored ABPP probes for enhanced visualization of NOTUM in biological systems.

We first sought to establish whether NOTUM activity could be assayed with serine hydrolase (SH)-directed fluorophosphonate (FP) ABPP probes.^[@ref21],[@ref22]^ Conditioned media (CM) from HEK293T cells transiently transfected with cDNAs encoding wild-type (WT) or a catalytically inactive (S232A) mutant of human NOTUM (or with a control protein METAP2) was treated with a rhodamine-tagged FP probe (FP-Rh) and analyzed by gel-based ABPP, which revealed a robustly FP-Rh-labeled ∼52 kDa band (predicted MW of full-length NOTUM is 54 kDa) in WT-NOTUM-transfected, but not S232A-NOTUM- or METAP2-transfected cell media ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A and [Supplementary Figure 1](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)). Western blotting with a commercial anti-NOTUM antibody also identified this 52 kDa protein, as well as a slightly higher MW protein (∼54 kDa) that could represent full-length unprocessed NOTUM ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A). Notably, the higher MW form of NOTUM, which matches the predicted molecular weight of the full-length protein prior to signal peptide cleavage, showed much lower relative reactivity with the FP-Rh probe, suggesting that processing may be required to fully activate NOTUM.

![Discovery of NOTUM inhibitors from a set of activated ureas and carbamates by competitive ABPP. (A) Gel-based ABPP and Western blot analysis of conditioned media (CM) from HEK293T cells transiently transfected with cDNAs encoding WT-NOTUM, a catalytically inactive S232A-NOTUM, or control protein (METAP2). Gel-based ABPP was performed by incubating CM proteome with the FP-Rh probe (1 μM, 30 min, room temperature). Western blotting was performed with an anti-NOTUM antibody (Sigma-Aldrich HPA023041). (B) General structures of the triazole urea^[@ref18]^ and NHH carbamate^[@ref17]^ classes of SH-directed inhibitors. (C) Gel-based ABPP of a collection of triazole urea and NHH carbamate compounds against the CM of WT-NOTUM-transfected HEK293T cells. CM samples were pretreated with 10 μM compound (30 min, 37 °C) followed by FP-Rh (1 μM, 30 min, room temperature), prior to SDS-PAGE analysis and in-gel fluorescence scanning. (D,E) Structures (D) and concentration-dependent inhibition profiles (E) for two NHH carbamate inhibitors of NOTUM: **ABC28** and **ABC63**.](ml-2018-00191p_0001){#fig1}

Having established that NOTUM activity could be visualized by ABPP, we next screened a series of serine hydrolase-directed inhibitors containing triazole urea^[@ref18]^ and NHH carbamate^[@ref17]^ reactive groups (10 μM, 30 min pretreatment at 37 °C) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). A number of compounds from both structural classes blocked FP-Rh reactivity with NOTUM ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C), and among these, we selected two NHH carbamates, **ABC28** and **ABC63**, for follow-up studies, as we have found that this class of serine hydrolase inhibitors is generally less promiscuous than triazole ureas, while still affording the opportunity to derivatize both the staying and leaving groups to optimize potency and selectivity.

Concentration-dependent profiles revealed that **ABC28** showed superior potency for NOTUM inhibition compared to **ABC63** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). We next confirmed that endogenously produced NOTUM could be detected by ABPP in the conditional media from SW620 cells, a human colon cancer cell line with high NOTUM expression.^[@ref23]^ A strong FP-Rh-labeled, ∼52 kDa protein was detected in SW620 CM, and the FP-Rh reactivity of this protein was blocked by pretreatment with **ABC28** ([Supplementary Figure 1](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)). Using CM from SW620 cells as a convenient source of endogenous human NOTUM, we initiated structure--activity relationship (SAR) studies for NHH carbamate inhibitors of the enzyme.

###### IC~50~ Values for NHH Carbamate Inhibitors of NOTUM Determined by Competitive Gel-Based ABPP[a](#t1fn1){ref-type="table-fn"}

  compd    IC~50~ \[nM\] (95% CI)
  -------- ------------------------
  ABC28    677 (467--943)
  ABC63    1506 (1101--2065)
  ABC90    290 (221--441)
  ABC91    \>10 μM
  ABC92    200 (156--275)
  ABC99    13 (9.39--17.5)
  ABC101   \>10 μM

Data represent average values with confidence intervals (CI) provided for three independent experiments.

Substitution of chlorine for bromine on the distal phenyl ring of the leaving group of **ABC28**, combined with positional scanning of the halogen substituent (**ABC90--ABC92**; [Supplementary Figure 2A](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)), yielded two compounds, **ABC90** (*p*-Cl) and **ABC92** (*o*-Cl), that showed substantially improved potency for NOTUM inhibition (IC~50~ values \< 300 nM; [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), while the *m*-Cl analogue (**ABC91**) completely lost activity ([Supplementary Figure 2B](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)). We next evaluated the selectivity of **ABC90** by gel-based ABPP using soluble and membrane proteomes of SW620 cells, which express a more diverse array of serine hydrolase activities compared to the CM fraction of these cells ([Supplementary Figure 2C](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)). Among the FP-Rh-labeled proteins in SW620 soluble and membrane proteomes, only a single major site of **ABC90** cross reactivity was observed; a 35 kDa protein that we suspected was ABHD6 ([Supplementary Figure 2C](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)), a common target of carbamate serine hydrolase inhibitors.^[@ref17],[@ref20]^ We also noted, however, that the NHH carbamate scaffold represented by **ABC90** was similar to that of a previously reported inhibitor of the serine hydrolase protein palmitoyl thioesterase 1 (PPT1),^[@ref17]^ and we accordingly found that **ABC90** was a potent inhibitor of PPT1, as determined using the PPT1-directed ABPP probe **ABC45**([@ref17]) ([Supplementary Figure 2D](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)). In contrast, the alternative NHH carbamate hit compound for NOTUM, **ABC63**, did not inhibit PPT1 at concentrations up to 10 μM ([Supplementary Figure 2D](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)). These data are consistent with our previous research on PPT1, where we observed that the enzyme shows reduced reactivity with NHH carbamates bearing smaller and less extended staying groups.^[@ref17]^ We therefore reasoned that a compound, referred to hereafter as **ABC99** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), possessing the staying group of **ABC63** and leaving group of **ABC90** might constitute a potent NOTUM inhibitor that does not cross-react with PPT1.

![Generation and characterization of **ABC99**, a potent and selective NOTUM inhibitor. (A) Structure of **ABC99** and inactive control compound **ABC101**. (B) Concentration-dependent inhibition of NOTUM by **ABC99** and **ABC101** as measured by competitive ABPP using SW620 CM. (C,D) Competitive ABPP of SW620 cells treated *in situ* with **ABC99** (indicated concentrations, 2 h, 37 °C) followed by exposure to the general serine hydrolase probe FP-Rh (C) or the PPT1-directed probe **ABC45** (D). (E) Quantitative MS-based ABPP of SW620 CM treated with **ABC99** (0.5 or 10 μM, 1 h, 37 °C), **ABC101** (10 μM, 1 h, 37 °C), or DMSO. Serine hydrolases were enriched with FP-biotin (4 μM, 1 h, room temperature) and streptavidin chromatography. After on-bead trypsin digestion, peptides were isotopically labeled with heavy (DMSO) or light (compound) formaldehyde, then combined and processed for MS-based analysis.^[@ref24]^ Ratios are displayed as light/heavy; therefore, low values indicate inhibition. Data for each experimental group represent median aggregate peptide ratios across two independent experiments +/− SEM. (F) **ABC99**, but not **ABC101**, preserves Wnt-3A activity in the presence of NOTUM in a concentration-dependent manner as measured using a Super TOPflash assay. Media from Wnt-3A expressing L-cells were incubated with inhibitor treated media from SW620 cells and then added to HEK293T-STF cells, which express luciferase in response to activation of the canonical Wnt pathway. Data represent average values with confidence intervals (CI) provided for four independent experiments.](ml-2018-00191p_0002){#fig2}

**ABC99** inhibited NOTUM with an IC~50~ value of 13 nM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) and showed excellent selectivity across the serine hydrolase family, as initially assessed by gel-based ABPP of soluble and membrane proteomes from SW620 cells ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C,D). These ABPP experiments were performed using both FP-Rh and **ABC45** probes and thus confirmed that PPT1 also did not cross-react with **ABC99** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D). We next evaluated the selectivity of **ABC99** (0.5 and 10 μM) by quantitative mass spectrometry (MS)-based ABPP^[@ref24]^ in both the CM and SW620 *in situ* treated cells. These data confirmed the inhibition of NOTUM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}E) with virtually no cross-reactivity with the 64 additional serine hydrolases quantified by MS-ABPP ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}E and [Supplementary Figure 3](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf) and [Supplementary Data Set 1](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_002.xlsx)). A partial, concentration-dependent blockade of ABHD6 was observed, but only ∼50% of this enzyme was inhibited at concentrations of **ABC99** (0.5 μM) that fully blocked NOTUM. We also noted that **ABC99** more completely inhibited secreted ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}E) compared to cellular ([Supplementary Figure 3](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)) NOTUM, which could reflect that the latter fraction contains a greater proportion of incompletely processed NOTUM.

In the course of evaluating the SAR of NHH carbamate inhibitors, we discovered that conversion of the basic tertiary amine in **ABC99** to an amide furnished a compound **ABC101** that lost inhibitory activity for NOTUM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A,B,E) but maintained inhibition of ABHD6 ([Supplementary Figure 3](#notes1){ref-type="notes"}). We therefore considered that **ABC101** could serve as a useful inactive control probe for biological studies.

We next tested whether **ABC99** could counteract the suppression of Wnt signaling by NOTUM in a cellular assay. Using a luciferase reporter cell line responsive to Wnt activation (HEK293T-STF),^[@ref25]^ we found that exposure of cells to a combination of NOTUM-expressing CM (harvested from SW620 cells) preincubated with either **ABC99** or the control compound **ABC101** and CM from Wnt3A-producing L-cells^[@ref26]^ resulted in the concentration-dependent preservation of Wnt signaling in the presence of **ABC99**, but not **ABC101** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}F). The IC~50~ value for **ABC99**-mediated preservation of Wnt3A activity ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}F and [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) was moderately higher than the IC~50~ value for inhibition of NOTUM measured by ABPP ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), which could indicate that substantially more than 50% of NOTUM needs to be inhibited for protection of Wnt-mediated cell signaling.

###### EC~50~ Values for Preservation of Wnt Activity by ABC99 and ABC101 Determined Using a Super TOPflash Assay[a](#t2fn1){ref-type="table-fn"}

  compound   IC~50~ \[nM\] (95% CI)
  ---------- ------------------------
  ABC99      89 (55--150)
  ABC101     \>5 μM

Data represent average values with confidence intervals (CI) provided for four independent experiments.

Considering that NOTUM is a secreted enzyme with highly regulated expression, including induction by Wnt signaling itself,^[@ref12]^ it would be valuable to generate probes to specifically monitor the activity of this enzyme in native biological systems. Toward this end, we incorporated an alkyne into the staying group of the **ABC99** scaffold to generate a clickable probe termed **ABC99yne** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). We found that **ABC99yne** blocked the FP-Rh reactivity of NOTUM in CM from SW620 cells with a sub-micromolar IC~50~ value, and treatment of these samples with a rhodamine-azide reporter tag^[@ref27]^ under copper-mediated azide--alkyne cycloaddition (CuAAC, or click) chemistry conditions^[@ref28],[@ref29]^ resulted in the highly selective labeling of NOTUM with no other cross-reactive proteins observed in the CM ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B) or cellular lysate ([Supplementary Figure 4](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf)) of SW620 cells (0.1 μM **ABC99yne** probe).

![Development of **ABC99yne**, a clickable analogue of **ABC99** for visualizing NOTUM activity in biological samples. (A) Structure of **ABC99yne**. (B) ABPP gel showing competitive blockade of FP-Rh labeling (left lanes) and direct labeling (right lanes) of NOTUM by **ABC99yne** in SW620 CM. Samples were pretreated with **ABC99yne** at the indicated concentrations (30 min, 37 °C) and then treated with FP-Rh (1 μM, 30 min, room temperature) or subjected to CuAAC conditions with a Rh--N~3~ tag prior to SDS-PAGE analysis.](ml-2018-00191p_0003){#fig3}

We have described, to our knowledge, the first potent and selective irreversible inhibitors of the Wnt-deacylating enzyme NOTUM. The most advanced compound, **ABC99**, blocks NOTUM activity with low-nanomolar potency (IC~50~ value = 13 nM) and excellent selectivity as assessed with serine hydrolase-directed ABPP probes and by global proteomic reactivity analysis using a clickable probe analogue (**ABC99yne**). Over the past decade, many studies have emphasized the important role that NOTUM plays as a negative regulator of Wnt signaling in diverse biological processes, but virtually all of these efforts have relied on molecular biology (e.g., genetic) methods to perturb NOTUM function.^[@ref10],[@ref11],[@ref30],[@ref31]^ We believe that the covalent inhibitors and related chemical probes (inactive control and clickable probes) described herein will provide valuable complementary tools to the limited set of noncovalent inhibitors reported previously^[@ref14],[@ref15]^ to characterize the biological effects of pharmacologically inactivating NOTUM in diverse physiological and disease processes. Future studies of interest include testing the proteome-wide reactivity of **ABC99** using the **ABC99yne** probe combined with MS-based ABPP analysis;^[@ref17]^ directly measuring Wnt palmitoleate modification^[@ref10]^ following exposure of biological systems to **ABC99**; and assessing the effect of **ABC99** on Wnt signaling in vivo. Related to the last objective, we note that NOTUM appears to have a restricted tissue distribution in vivo (<http://www.humanproteomemap.org/>), which may provide clues as to the specific areas of Wnt biology that are most strongly influenced by NOTUM-mediated deacylation.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.8b00191](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.8b00191).Supplemental figures, biological methods, synthetic procedures, and characterization for all compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_001.pdf))Supplementary proteomics data set containing data from mass spectrometry experiments ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00191/suppl_file/ml8b00191_si_002.xlsx))

Supplementary Material
======================

###### 

ml8b00191_si_001.pdf

###### 

ml8b00191_si_002.xlsx

^†^ Department of Chemistry, University of Washington, Seattle, WA 98195, USA.

^‡^ R.S. and A.B.C. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

The authors declare the following competing financial interest(s): B.F.C. is a cofounder and scientific advisor to Abide Therapeutics, a biotechnology company interested in developing SH inhibitors as therapeutics.

This work was supported by the NIH (DA033760, CA193994) and the Skaggs Institute for Chemical Biology.

ABPP

:   activity-based protein profiling

CM

:   conditioned media

FP

:   fluorophosphonate

NHH

:   *N*-hydroxyhydantoin
